2022 ISPE Annual Meeting & Expo Keynote Robert Weker and 2021-2022 ISPE Board Chair Jörg Zimmermann
Every patient is unique. Every cancer journey is unique. As a three-time cancer ‘sur-thrivor,’ Robert Weker, Principal, Weker Advisors LLC, and his family have faced the many challenges of this disease.
During #ISPEAM22, Robert provided his insights on his journey(s) - including participation in a clinical trial, finding the best medical team, and work and financial implications.
2021-2022 ISPE Board Chair Jörg Zimmermann, Vice President, Vetter Development Service, External Affairs, Vetter Pharma, spoke to ISPE’s mission and vision at #ISPEAM22
2022 ISPE Annual Meeting & Expo Keynote Speakers Julie Kim and Andres Angelani
Keynote Julie Kim, President, U.S. Business Unit and U.S. Country Head, Takeda, shared with attendees how both she, and Takeda, approach collaboration and partnership in a way that keeps the patient front and center.
Keynote Andres Angelani, Global Head of Digital Engineering at Cognizant, shared his experiences working with multiple companies and across diverse industries to develop not only a transformative vision to meet the new business expectations, but also to implement that vision in order to realize successful outcomes.
Keynote Joydeep Ganguly, Senior Vice President, Corporate Operations, Gilead Sciences, is closing out the event with his presentation “Reimaging Value through Operations – How the Pandemic Redefined Emerging Trends in our Sector.”
Following an unprecedented two years in which the pharmaceutical industry has faced numerous challenges posed by the global pandemic, pharmaceutical manufacturing has had to react and respond to meet the rapidly changing requirements and timelines. This has necessitated a radical rethink in how we approach pharmaceutical manufacturing and how we meet the expectations of the market and patients...
In 2022, supply chain challenges have been present in the news every day. Whether it is oil, computer chips, drugs, or baby formula, we have been made aware about how fragile our supply chains are and how many companies are hard at work trying to shore up current supply lines, while preparing for a better future with innovative solutions. Within our own industry, supply chain issues and...
As we emerge from a global pandemic that has impacted all aspects of life – both personal and professional, we, in the pharmaceutical industry, should take the opportunity to reflect, learn, and look forward to the exciting changes and innovations within our industry. The past two years have seen unprecedented innovations in the development and manufacture of products that provide the promise...
The industry is in the process of a transformation that was sped up by the pandemic, which enhanced innovation and collaboration. Applying what has been learned over the last three years to update pharmaceutical companies’ approaches to development and implementation is key as the industry crafts its strategies in an increasingly digital and global environment. The keynote presentations on 1...
The 2022 ISPE Annual Meeting & Expo opened with three keynote addresses exploring quality from a key FDA leader’s point of view, a major pharmaceutical company’s ongoing journey of transformation into an organization that is prepared to adapt to the changing world, and a unique patient perspective with a patient presenter who is also a member of the pharmaceutical community.
ISPE’s Transportable/Point of Care (PoC) Manufacturing Technology team, a working group under the Product Quality Lifecycle Implementation (PQLI)® committee, is presenting a session entitled Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective at the 2022 ISPE Annual Meeting & Expo on Monday, 31 October at 1100–1230 as part of the...
Emerging Leaders (EL) within the pharmaceutical industry have been invited from around the world to participate in the 2022 ISPE Annual Meeting & Expo Program Committee. This unique opportunity allows...
The industry is continuously evolving to meet new requirements. Many of these requirements include adhering to global regulatory harmonization, improving supply chain robustness, minimizing drug shortages, reducing the complexity of managing product life cycles, and reducing the environmental impact of pharmaceutical processes. At the
Digital transformation is the novel use of digital technology, including instrumentation and control systems, to solve traditional problems in a transformative manner. These digital solutions enable inherently new types of innovation and creativity, rather than simply enhancing, and supporting traditional methods.
While everyone is facing new speed to market expectations, we should consider and discuss why global regulatory barriers are increasing, why science- and risk-based strategies often mean more data are required, and why regulatory approval for new technologies and new medicines seems more challenging than ever before. We can no longer afford to delay innovation, product and process...
Following an unprecedented two years in which the pharmaceutical industry has faced numerous challenges posed by the global pandemic, pharmaceutical manufacturing has had to react and respond to meet the rapidly changing requirements and timelines. This has necessitated a radical rethink in how we approach pharmaceutical manufacturing and how we meet the expectations of the market and patients...
In 2022, supply chain challenges have been present in the news every day. Whether it is oil, computer chips, drugs, or baby formula, we have been made aware about how fragile our supply chains are and how many companies are hard at work trying to shore up current supply lines, while preparing for a better future with innovative solutions. Within our own industry, supply chain issues and...
As we emerge from a global pandemic that has impacted all aspects of life – both personal and professional, we, in the pharmaceutical industry, should take the opportunity to reflect, learn, and look forward to the exciting changes and innovations within our industry. The past two years have seen unprecedented innovations in the development and manufacture of products that provide the promise...
The industry is in the process of a transformation that was sped up by the pandemic, which enhanced innovation and collaboration. Applying what has been learned over the last three years to update pharmaceutical companies’ approaches to development and implementation is key as the industry crafts its strategies in an increasingly digital and global environment. The keynote presentations on 1...
The 2022 ISPE Annual Meeting & Expo opened with three keynote addresses exploring quality from a key FDA leader’s point of view, a major pharmaceutical company’s ongoing journey of transformation into an organization that is prepared to adapt to the changing world, and a unique patient perspective with a patient presenter who is also a member of the pharmaceutical community.
ISPE’s Transportable/Point of Care (PoC) Manufacturing Technology team, a working group under the Product Quality Lifecycle Implementation (PQLI)® committee, is presenting a session entitled Transportable, Small Footprint Biopharmaceutical Manufacturing Facilities: A Regulatory Perspective at the 2022 ISPE Annual Meeting & Expo on Monday, 31 October at 1100–1230 as part of the...
Emerging Leaders (EL) within the pharmaceutical industry have been invited from around the world to participate in the 2022 ISPE Annual Meeting & Expo Program Committee. This unique opportunity allows...
The industry is continuously evolving to meet new requirements. Many of these requirements include adhering to global regulatory harmonization, improving supply chain robustness, minimizing drug shortages, reducing the complexity of managing product life cycles, and reducing the environmental impact of pharmaceutical processes. At the
Digital transformation is the novel use of digital technology, including instrumentation and control systems, to solve traditional problems in a transformative manner. These digital solutions enable inherently new types of innovation and creativity, rather than simply enhancing, and supporting traditional methods.
While everyone is facing new speed to market expectations, we should consider and discuss why global regulatory barriers are increasing, why science- and risk-based strategies often mean more data are required, and why regulatory approval for new technologies and new medicines seems more challenging than ever before. We can no longer afford to delay innovation, product and process...
Following an unprecedented two years in which the pharmaceutical industry has faced numerous challenges posed by the global pandemic, pharmaceutical manufacturing has had to react and respond to meet the rapidly changing requirements and timelines. This has necessitated a radical rethink in how we approach pharmaceutical manufacturing and how we meet the expectations of the market and patients...
In 2022, supply chain challenges have been present in the news every day. Whether it is oil, computer chips, drugs, or baby formula, we have been made aware about how fragile our supply chains are and how many companies are hard at work trying to shore up current supply lines, while preparing for a better future with innovative solutions. Within our own industry, supply chain issues and...
As we emerge from a global pandemic that has impacted all aspects of life – both personal and professional, we, in the pharmaceutical industry, should take the opportunity to reflect, learn, and look forward to the exciting changes and innovations within our industry. The past two years have seen unprecedented innovations in the development and manufacture of products that provide the promise...
